Philip R. Clingan

Wollongong, NSW, AU 
Wollongong, NSW, AU 

Overview

Philip Clingan practices practicing medicine in Wollongong, Australia.

His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Colorectal Cancer, and Lung Metastases.

He is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Wollongong, NSW, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological
Study Drugs: MGD013, MGD013+Margetuximab
Study Phase: Phase 1
A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination With Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer
A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination With Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: November 13, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

27 Total Publications

A Prospective, Cross-Sectional, Multicenter Study Evaluating a Multi-Target Blood Protein in Vitro Diagnostic Test for Colorectal Cancer.
A Prospective, Cross-Sectional, Multicenter Study Evaluating a Multi-Target Blood Protein in Vitro Diagnostic Test for Colorectal Cancer.
Journal: Journal of gastrointestinal cancer
Published: December 07, 2025

Frequently Asked Questions about Philip R. Clingan

Is Philip R. Clingan a top-rated expert for Non-Small Cell Lung Cancer (NSCLC)?

MediFind is an objective health platform that identifies experts based on real-world data. Philip R. Clingan is classified as an Experienced expert for Non-Small Cell Lung Cancer (NSCLC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Philip R. Clingan participate in research or clinical trials?

Yes. Philip R. Clingan has published 27 articles and abstracts on conditions like Non-Small Cell Lung Cancer (NSCLC). You can view a list of Philip R. Clingan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Clingan's expertise for a condition
ConditionClose
        View All 10 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile